Business
Avalo is a clinical-stage biotech focused on IL-1 beta treatments for immune-mediated inflammatory diseases, led by AVTX-009 in hidradenitis suppurativa.
Avalo revenue fell to $59K, losses widened, equity fell, and insider activity was sales-only.
The read at a glance✓ Audited against SEC data
- Business mix — AVTX-009 immune-inflammatory pipelineNote
- Revenue — Revenue fell 86.6%Watch
- Losses — Net loss widened to $78.3MWatch
- Cash — Cash from ops worsenedWatch
- Balance sheet — Equity fell 37.6%Watch
- Insiders — 0 buys / 13 sellsWatch
- Accounting — Altman-Z distress; other screens unavailableWatch
Where the revenue comes from
Fiscal 2025, as Avalo Therapeutics, Inc. reports it. History and quarterly detail are in the app.
- Product revenue, net$59K
Leadership changes
From Avalo Therapeutics, Inc.'s own filings, the day they're filed.
- Ron Philip · director · appointmenteff. 2026-06-23
- Kevin Lind · director · appointmenteff. 2025-10-01
- Rita Jain · director · appointmenteff. 2025-06-17
Latest filings
- 8-K · Company announcement2026-08-06
- 10-Q · Quarterly report2026-08-06
- 8-K · Company announcement2026-06-23
- 8-K · Company announcement2026-06-16
- 8-K · Company announcement2026-06-12
In the full recordFree for 14 days
- What changed🔒
- Insider signal🔒
- Growth quality🔒
- Margins & accounting🔒
- Capital allocation🔒
- Real risks🔒
- The long arc🔒
- Company history🔒
- Main tension🔒
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about Avalo Therapeutics, Inc., every answer cited to the official filings🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.